首页> 外文期刊>Journal of experimental & clinical cancer research : >XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway
【24h】

XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway

机译:XAV939,一种tankyrase 1抑制剂,通过抑制Wnt /β-catenin信号通路促进神经母细胞瘤细胞系的细胞凋亡

获取原文
           

摘要

Background Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. The present treatment including surgery, chemotherapy and radiation, which have only 40% long-term cure rates, and usually cause tumor recurrence. Thus, looking for new effective and less toxic therapies has important significance. XAV939 is a small molecule inhibitor of tankyrase 1(TNKS1). The objective of this study is to investigate the effect of XAV939 on the proliferation and apoptosis of NB cell lines, and the related mechanism. Methods In the present study, we used both XAV939 treatment and RNAi method to demonstrate that TNKS1 inhibition may be a potential mechanism to cure NB. MTT method was used for determining the cell viability and the appropriate concerntration for follow-up assays. The colony formation assay, Annexin V staining and cell cycle analysis were used for detecting colony forming ability, cell apoptosis and the percentage of different cell cycle. The Western blot was used for detecting the expression of key proteins of Wnt/ beta-catenin (Wnt/β-catenin) signaling pathway. Results The results showed that TNKS1 inhibition decreased the viability of SH-SY5Y, SK-N-SH and IMR-32 cells, induced apoptosis in SH-SY5Y as well as SK-N-SH cells, and led to the accumulation of NB cells in the S and G2/M phase of the cell cycle. Moreover, we demonstrated TNKS1 inhibition may in part blocked Wnt/β-catenin signaling and reduced the expression of anti-apoptosis protein. Finally, we also demonstrated that TNKS1 inhibition decreased colony formation in vitro. Conclusions These findings suggested that TNKS1 may be a potential molecule target for the treatment of NB.
机译:背景神经母细胞瘤(NB)是儿童时期最常见的颅外实体瘤。目前的治疗包括外科手术,化学疗法和放射疗法,它们只有40%的长期治愈率,并且通常会导致肿瘤复发。因此,寻找新的有效且毒性较小的疗法具有重要意义。 XAV939是tankyrase 1(TNKS1)的小分子抑制剂。这项研究的目的是研究XAV939对NB细胞系增殖和凋亡的影响及其相关机制。方法在本研究中,我们同时使用XAV939治疗和RNAi方法来证明TNKS1抑制可能是治愈NB的潜在机制。使用MTT方法确定细胞活力并进行后续测定。用菌落形成试验,膜联蛋白V染色和细胞周期分析来检测菌落形成能力,细胞凋亡和不同细胞周期的百分比。 Western blot用于检测Wnt /β-catenin(Wnt /β-catenin)信号通路关键蛋白的表达。结果结果表明,TNKS1抑制作用降低了SH-SY5Y,SK-N-SH和IMR-32细胞的活力,诱导了SH-SY5Y和SK-N-SH细胞的凋亡,并导致NB细胞的积累在细胞周期的S和G2 / M期。此外,我们证明了TNKS1抑制作用可能部分阻断了Wnt /β-catenin信号传导并降低了抗凋亡蛋白的表达。最后,我们还证明了TNKS1的抑制作用会降低体外菌落的形成。结论这些发现表明,TNKS1可能是NB治疗的潜在分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号